A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy

NCT07387094 · Recruiting

Last updated 2026-05-28

This clinical trial is testing the drug XW003 in adults with obesity and obstructive sleep apnea who are not using positive airway pressure therapy to see how it affects their sleep apnea symptoms.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 140 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2026-02 · est. completion 2027-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07387094 ↗

Description as written by the study sponsor.

The aim of the study is to assess the efficacy and safety of XW003 injections in obese participants with OSA but not receiving PAP

Treatments tested

XW003 injection also known as Ecnoglutide injection Drug

subcutaneous injection
placebo with matching volume Drug

subcutaneous injection

Main thing measured	Change from baseline in Apnea-Hypopnea Index (AHI)
Sponsor	Hangzhou Sciwind Biosciences Co., Ltd.
Conditions studied	OSA - Obstructive Sleep Apnea, Obesity
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07387094 ↗